Children conceived through assisted reproductive technology (ART) were modestly more likely to develop asthma, allergic ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...
The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback